SELVAS Healthcare, Inc (208370) Fair Value & Analysis
Healthcare · KR · Market cap 63.5B KRW
Fair value as of: Jul 22, 2026
From 11 valuation models · updated 19 days ago
Share price +3.8% over the past month.
Below-average quality, and screening another 23% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (2,193 KRW). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The models converge in a tight band (1,928 KRW to 2,193 KRW), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 1,707 KRW – 12,870 KRW · fair‑value band 1,928 KRW – 2,193 KRW · the 2,840 KRW price screens above the 2,193 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
SELVAS Healthcare, Inc (208370) currently trades at 2,840 KRW, while our model-based Fair Value estimate is 2,193 KRW, implying the stock looks roughly 22.8% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, SELVAS Healthcare, Inc generated revenue of 30.2B KRW at a net margin of 56.0%. Revenue declined 8.8% year over year. It earns a return on equity of 22.8%. Net debt stands at 3.1B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 1,928 KRW (bear case) to 2,193 KRW (bull case); at 2,840 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -23%, 208370 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: Growth Earnings (2,789 KRW) versus Earnings-Based (757.62 KRW). Highest evidence: Growth-Adj P/E (68).
Notify me when 208370 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SELVAS Healthcare, Inc. operates as a medical device company in South Korea. The company provides body composition analyzers and automatic blood pressure monitors for hospitals.
Full company description
SELVAS Healthcare, Inc. operates as a medical device company in South Korea. The company provides body composition analyzers and automatic blood pressure monitors for hospitals. It also offers Braille Sense notetakers and other products for blind and visually impaired people under the HIMS brand name, as well as provides digital health products under the ACCUNIQ brand name. In addition, The company provides daisy players, handheld, and desktop magnifiers. Its products are used in hospitals, medical facilities, doctor's offices, weight loss centers, Fitness Centers, nursing homes, public health facilities, and retail locations. The company was formerly known as Jawon Medical Co., Ltd. and changed its name to SELVAS Healthcare, Inc. in September 2016. SELVAS Healthcare, Inc. was founded in 1993 and is headquartered in Daejeon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SELVAS Healthcare, Inc reported revenue of 30.8B KRW in FY2025 versus 29.1B KRW in FY2021, a compound +1.5%/yr. Reported net income was 3.9B KRW in FY2025, compounding +12.0%/yr from FY2021.
208370 screens 23% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare SELVAS Healthcare, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SELVAS Healthcare, Inc (208370) overvalued or undervalued?
What is the fair value of 208370?
What is the quality score of 208370?
What is the revenue of SELVAS Healthcare, Inc (208370)?
What is the net profit margin of 208370?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SELVAS Healthcare, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.